ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cell-immunotherapy-focused Adicet Bio has launched with $51 million in its first round of financing led by OrbiMed and including Novartis Venture Fund and Pontifax. In clinical trials, its cellular therapies reengineer a patient’s own T cells to home in on and kill cancer cells. Those highly personalized treatments present manufacturing challenges and may prove to be expensive. Adicet is also working on universal immune cell therapies, which would allow multiple patients to be treated. Adicet also announced the acquisition of Applied Immune Technologies, which is developing immunotherapies that target the intracellular proteome.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X